CELLINK BIO X wins the Grand Award of Design.

BIO X, the 3D bioprinter for human tissue is awarded The Grand Award of Design 2019. The company behind this innovation is CELLINK who, together with Semcon’s design department, have developed a user-friendly, and original design for the bioprinter. 

The Swedish Teknikföretagen’s Grand Award of Design highlights design as a key to competitiveness and profitability. In the yearly competition, a jury of prominent experts in design chooses a winner.

“An important acknowledgment for us, and for BIO X. With well-designed software and functional product design it has been possible for us to reach out with 3D Bioprinting to hundreds of labs worldwide.” says Anton Andren, Hardware Project Manager at CELLINK. 

The BIO X 3D bioprinter uses a unique bioink to print human tissue. CELLINK has commercialized products such as bioink and the bioprinter BIO X. These products are being usedin life science research to allow medical tests to be carried out on human tissue. 

The motivation of the jury:

CELLINK has not only succeeded in building a revolutionary bioprinter, but has also made it available to researchers through extensive cost-effective collaborations. Through a smart futuristic design that has a low threshold in use, it has been created to solve complex problems.

For further information, please contact:

Erik Gatenholm, CEO                                                               Gusten Danielsson, CFO

Phone: EU +46 73 267 00 00                                                   Phone: +46 70 991 86 04
US +1 (650) 515 5566                                                              US+1 (857) 332 2138 

Email:[email protected]                                                              Email:[email protected] 


CELLINK is the leading 3D-bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at: [email protected].

Latest press releases